756760-16-4

Usage

Explanation

The compound consists of 9 carbon atoms, 11 hydrogen atoms, 1 nitrogen atom, and 2 oxygen atoms in its molecular structure.
2. Derivative of pyrrole

Explanation

It is a modified version of the aromatic heterocyclic organic compound pyrrole, which consists of a five-membered ring with one nitrogen atom and four carbon atoms.
3. Carboxylic acid

Explanation

The compound contains a carboxyl functional group (-COOH), which is a combination of a carbonyl group (C=O) and a hydroxyl group (-OH), giving it acidic properties.
4. Pyrrole carboxylic acid

Explanation

It is a type of carboxylic acid that is part of the pyrrole family, characterized by the presence of the pyrrole ring in its structure.
5. Three methyl groups attached

Explanation

The pyrrole ring has three methyl groups (-CH3) attached to it, which contribute to its unique chemical and physical properties.
6. Research and industrial applications

Explanation

The compound is used in various research and industrial applications, such as organic synthesis and pharmaceutical manufacturing, due to its unique structure and properties.
7. Building block for new compounds and materials

Explanation

Its distinctive structure and properties make it a valuable component in the development of new compounds and materials, further expanding its potential applications in various fields.

Upstream product

• 55770-79-1 ethyl 1,3,5-trimethylpyrrole-2-carboxylate 
• 2199-44-2 3,5-dimethyl-2-ethoxycarbonyl-1H-pyrrole 

Relevant academic research and scientific papers

Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents

Chronic hepatitis B viral infection is a significant health problem world-wide, and currently available antiviral agents suppress HBV infections, but rarely cure this disease. It is presumed that antiviral agents that target the viral nuclear reservoir of transcriptionally active cccDNA may eliminate HBV infection. Through a series of chemical optimization, we identified a new series of glyoxamide derivatives affecting HBV nucleocapsid formation and cccDNA maintenance at low nanomolar levels. Among all the compounds synthesized, GLP-26 displays a major effect on HBV DNA, HBeAg secretion and cccDNA amplification. In addition, GLP-26 shows a promising pre-clinical profile and long-term effect on viral loads in a humanized mouse model.

MONOMER AND MULTIMERIC ANTI-HBV AGENTS

The present invention is directed to compounds, compositions and methods for preventing, treating or curing hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.

ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS

The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.

ORNITHINE DERIVATIVE

Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. The present inventors have made extensive studies on an ornithine derivative having an antagonistic action against an EP4 receptor, and as a result, they have found that by introducing cycloalkanediyl at a C terminal of the ornithine part of the compound of the present invention, the physicochemical properties such as solubility, and the like can be improved, thereby giving further preferred properties as a pharmaceutical. Therefore, they have completed the present invention. The compound of the present invention exhibits a good antagonistic action against an EP4 receptor, and thus, it is useful as a therapeutic agent for chronic renal insufficiency and diabetic nephropathy.